MediPharm Labs Appoints Former Johnson & Johnson Group Product Director as Chief Strategy Officer

Visit the MediPharm Labs Investor Dashboard and stay up to date with data-driven, fact based due diligence for active traders and investors.


New Pharma Executive Position Created to Advance Corporate Strategy, Global Growth and Strategic Partnerships

TORONTO, April 29, 2019 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSXV: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to announce the appointment of Braden Fenske as Chief Strategy Officer effective April 29, 2019. In this newly created executive role, Mr. Fenske will be responsible for advancing the Company’s strategic corporate initiatives in collaboration with the Company’s executives and operational teams across the company. Leveraging his extensive relationships within the healthcare industry, Mr. Fenske will also focus on accelerating domestic and global growth and expanding strategic partnerships to create additional value and opportunities for MediPharm Labs’ new products and growing portfolio of cannabis and non-cannabis customers.

Mr. Fenske brings to the Company 20 years of diverse and highly specialized experience within the global healthcare industry and prior to that the adult beverage industry. Over a 15-year career with the Johnson & Johnson Group of Companies (“J&J”), Mr. Fenske has developed unique and extensive experience within the pharmaceutical and medical device sectors leading product development, marketing, global strategy and operations that spanned multiple therapeutic areas in the U.S. and among global healthcare markets. Most recently, Mr. Fenske served as Group Product Director, Global Strategic Marketing for Biosense Webster Inc., a J&J Company. He managed J&J’s Medical Devices’ “next billion-dollar new product launch” upon its FDA approval in the USA and CE mark in Europe. Mr. Fenske’s previous experience with Mark Anthony Brands Inc. and Molson Coors Brewing Co. also provides unique insights into the recreational consumer and the burgeoning edibles and cannabis based derivative product segments.

We are thrilled to have Braden join our team at this pivotal moment in our history. With our leading extraction industry performance and momentum, our expanding portfolio of products, increasing customer base and deep pipeline of growth opportunities, we have demonstrated a clear potential for accelerated revenue growth.

Patrick McCutcheon, Chief Executive Officer, MediPharm Labs

Braden’s proven record of success developing operational growth strategies, his unique understanding of the pharmaceutical and medical delivery systems industry, and his U.S. and worldwide healthcare relationships, will strengthen MediPharm Labs’ position as a trusted partner for customers, and clinical trials, as we remain at the leading edge of the industry and achieve our growth potential in this rapidly evolving market.

About Braden Fenske, Chief Strategy Officer

Braden joins MediPharm Labs from Johnson & Johnson Group of Companies, bringing over 20 years of experience in diverse strategic, commercial, new product planning, and business development roles predominantly in Pharmaceuticals and Medical Devices industries.

Most recently, Braden served as Group Product Director, Global Strategic Marketing for Biosense Webster Inc., a J&J Company, with more than 1,300 professionals in 40 countries around the world, recognized worldwide as a leader in the science behind the diagnosis and treatment of cardiac arrhythmias. At Biosense Webster, he led the strategy and execution of J&J’s “most important New Product launch in the last decade” and facilitated product development from Research & Development through to commercial launch.

In his 15-year career with J&J in Canada and the USA (J&J Medical Devices, Biosense Webster Inc., Janssen Inc.), Braden held progressive roles on an accelerated leadership path and was highly awarded with multiple wins in President’s & Performance Clubs, Standards of Leadership and President’s Innovation.

During his tenure with J&J, Braden also led various global marketing initiatives for medical devices, driving corporate strategy and innovative product launches to optimize market share and revenue. Earlier in his career, Braden worked at both Mark Anthony Brands Inc. and Molson Coors Brewing Co. with leadership development roles in sales, marketing and trade promotions. Braden holds a Bachelor of Commerce degree from the University of Alberta.

I am excited to be joining the MediPharm Labs’ team positioned at the forefront of this quickly evolving industry with demand for purified concentrates driving growth and innovation. I have been impressed by the depth and caliber of the talented management team, and the Company’s compelling platform to be the dominant provider of scaled cannabinoid based derivative products for medical and recreational consumers globally.

Braden Fenske, Chief Strategy Officer, MediPharm Labs

I look forward to working alongside these outstanding leaders to elevate MediPharm Labs’ position as a trusted partner and deliver our next stage of exponential growth.”

About MediPharm Labs Corp.

Founded in 2015, MediPharm Labs has the distinction of being the first company in Canada to become a licensed producer for cannabis oil production under the ACMPR without first receiving a cannabis cultivation licence. This expert focus on cannabis concentrates from our cGMP (current Good Manufacturing Practices) and ISO standard clean rooms and critical environments laboratory, allows MediPharm Labs to produce purified, pharmaceutical-like cannabis oil and concentrates for advanced derivative products. MediPharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream extraction methodologies and purpose-built facilities to deliver pure, safe and precisely-dosed cannabis products to patients and consumers. MediPharm Labs’ private label program is a high margin business for the Company, whereby it opportunistically procures dry cannabis flower and trim from its numerous product supply partners, to produce proprietary cannabis oil concentrate products for resale globally on a private label basis.

Through its subsidiary, MediPharm Labs Australia Pty. Ltd., MediPharm Labs has also completed its application process with the federal Office of Drug Control to extract and import medical cannabis products in Australia.

Original Press Release

For fact-based information on MediPharm Labs, view the company’s sponsored Investor Dashboard.

Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.

Published by NCV Newswire
NCV Newswire
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.

Get Our Sunday Newsletter